Published in J Immunother Cancer on June 16, 2015
Identifying causal networks linking cancer processes and anti-tumor immunity using Bayesian network inference and metagene constructs. Biotechnol Prog (2016) 0.78
Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. Front Pharmacol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
Membrane vesicles as conveyors of immune responses. Nat Rev Immunol (2009) 14.72
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Clonal evolution in cancer. Nature (2012) 11.07
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov (2009) 7.01
How were new medicines discovered? Nat Rev Drug Discov (2011) 7.00
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
A whole-cell computational model predicts phenotype from genotype. Cell (2012) 5.98
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
CTLA-4: a negative regulator of autoimmune disease. J Exp Med (1996) 3.25
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
Encoding and decoding cellular information through signaling dynamics. Cell (2013) 2.96
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood (2012) 2.86
Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 2.86
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev (2006) 2.83
The economics of follow-on drug research and development: trends in entry rates and the timing of development. Pharmacoeconomics (2004) 2.65
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50
Twelve immunotherapy drugs that could cure cancers. Immunol Rev (2008) 2.45
Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther (2010) 2.38
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol (2013) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med (2003) 2.19
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature (2014) 2.05
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol (2013) 1.86
The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA (2005) 1.83
B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80
Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 1.75
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol (2003) 1.72
Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet (2001) 1.70
Phenotypic screening of small molecule libraries by high throughput cell imaging. Comb Chem High Throughput Screen (2003) 1.70
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res (2004) 1.55
CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med (2010) 1.48
Simultaneous imaging of small metabolites and lipids in rat brain tissues at atmospheric pressure by laser ablation electrospray ionization mass spectrometry. Anal Chem (2010) 1.45
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res (2000) 1.38
Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood (2005) 1.37
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res (2013) 1.30
The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 1.30
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Mass spectrometry imaging with high resolution in mass and space. Histochem Cell Biol (2013) 1.25
On-tissue protein identification and imaging by MALDI-ion mobility mass spectrometry. J Am Soc Mass Spectrom (2009) 1.23
A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology (2012) 1.20
Cell-based assays for high-throughput screening. Mol Biotechnol (2010) 1.19
Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther (2013) 1.17
The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin Exp Immunol (2010) 1.14
Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res (2007) 1.13
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med (2013) 1.08
Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. PLoS Comput Biol (2014) 1.05
Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One (2008) 1.05
Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan? Clin Pharmacol Ther (2013) 1.03
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res (2013) 1.02
Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes (2012) 1.02
Improved spatial resolution in the imaging of biological tissue using desorption electrospray ionization. Anal Bioanal Chem (2012) 1.01
Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. Diabetes (2010) 1.00
Cancer treatment: The killer within. Nature (2014) 0.97
Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther (2013) 0.97
Quantifying crosstalk among interferon-γ, interleukin-12, and tumor necrosis factor signaling pathways within a TH1 cell model. Sci Signal (2012) 0.97
Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice. Immunology (2014) 0.95
Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics (2013) 0.94
The single-probe: a miniaturized multifunctional device for single cell mass spectrometry analysis. Anal Chem (2014) 0.93
An evolutionary perspective on anti-tumor immunity. Front Oncol (2013) 0.91
Inferring relevant control mechanisms for interleukin-12 signaling in naïve CD4+ T cells. Immunol Cell Biol (2010) 0.91
Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. J Immunother (2010) 0.91
Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book (2012) 0.90
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J Diabetes Sci Technol (2009) 0.89
IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol (2009) 0.89
Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. PLoS One (2011) 0.89
Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther (2009) 0.89
Unraveling the physiological functions of exosome secretion by tumors. Oncoimmunology (2013) 0.88
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther (2014) 0.87
Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. Syst Biol (Stevenage) (2005) 0.87
Mechanistic systems modeling to guide drug discovery and development. Drug Discov Today (2012) 0.86
Integrating epidemiological data into a mechanistic model of type 2 diabetes: validating the prevalence of virtual patients. Ann Biomed Eng (2007) 0.86
In silico model-based inference: a contemporary approach for hypothesis testing in network biology. Biotechnol Prog (2014) 0.85
Immunotherapy's cancer remit widens. Nature (2013) 0.85
Immunotherapy: The path to win the war on cancer? Cell (2015) 0.84
Inferring alterations in cell-to-cell communication in HER2+ breast cancer using secretome profiling of three cell models. Biotechnol Bioeng (2014) 0.84
A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model. Integr Biol (Camb) (2012) 0.84
The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget (2014) 0.83